Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19245319 | FOOD COMPOSITION FOR REDUCING ALCOHOLIC HANGUP CONTAINING PLANT EXTRACT | June 2025 | August 2025 | Allow | 2 | 0 | 0 | No | No |
| 18844070 | METHOD FOR CHARACTERIZING INTERACTION FORCE BETWEEN LIGNIN AND CELLULASE | September 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18788758 | SYSTEMS AND METHODS FOR CELL CULTURING | July 2024 | March 2026 | Allow | 20 | 1 | 0 | No | No |
| 18833176 | METHOD OF DETERMINING GLUCOSE CONCENTRATION | July 2024 | April 2025 | Allow | 9 | 0 | 1 | No | No |
| 18734282 | HYBRID GEL COMPRISING PARTICULATE DECELLULARIZED TISSUE | June 2024 | July 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18652317 | MALLEABLE CONTROLLED RELEASE LOCAL ANESTHETIC WITH HEMOSTATIC COMPOSITION | May 2024 | June 2025 | Allow | 13 | 1 | 0 | No | No |
| 18636644 | METHOD OF PREPARING FERMENTED HERBAL EYE DROPS | April 2024 | July 2024 | Allow | 3 | 0 | 0 | No | No |
| 18440126 | TARGETING CANCER CELLS AND TISSUE USING FILAMENTOUS PLANT VIRUS PARTICLES | February 2024 | June 2025 | Allow | 16 | 2 | 0 | No | No |
| 18480172 | TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA) | October 2023 | December 2025 | Allow | 26 | 3 | 0 | No | No |
| 18460217 | REPAIR AND/OR RECONSTRUCTION OF INVERTEBRAL DISCS | September 2023 | September 2025 | Allow | 24 | 3 | 0 | No | No |
| 18229995 | BOTANICAL AND BACTERIAL EXTRACTS DISPLAYING RETINOL-LIKE ACTIVITY | August 2023 | April 2025 | Allow | 21 | 3 | 0 | Yes | No |
| 18209877 | BLOOD STORAGE CONTAINER CONTAINING AQUEOUS COMPOSITION FOR THE STORAGE OF RED BLOOD CELLS | June 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18209148 | COMPOSITIONS AND METHODS FOR ACTIVATING NK CELLS | June 2023 | May 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18034460 | PROCESS AND COMPOSITION FOR PRODUCTION OF ORGANIC SUBMICROMETRIC PARTICLES FROM WHOLE BIOLOGICAL MATTER | April 2023 | December 2025 | Allow | 32 | 1 | 0 | No | No |
| 18138285 | PERFORATED TISSUE GRAFT | April 2023 | February 2025 | Allow | 22 | 2 | 0 | Yes | No |
| 18134451 | METHOD FOR IMPROVED SPERM CELL POPULATIONS | April 2023 | March 2025 | Allow | 23 | 2 | 0 | No | No |
| 18194308 | METHODS AND DEVICES FOR SIMULTANEOUS OPTICAL IRRADIATION AND OSCILLATING MAGNETIC FIELD RADIATION OF A TARGET | March 2023 | September 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18117320 | TISSUE-DERIVED SCAFFOLDING MATERIALS AND METHOD FOR TISSUE FORMATION | March 2023 | June 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 18173333 | PULMONARY ADMINISTRATION OF PYOCINS FOR TREATING BACTERIAL RESPIRATORY INFECTIONS | February 2023 | August 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18011257 | CELL CULTURE DEVICE | December 2022 | December 2025 | Allow | 36 | 1 | 0 | No | No |
| 17982788 | METHODS AND ARTICLES FOR DELIVERING VIABLE CELLS INTO SOLID TISSUE | November 2022 | May 2024 | Abandon | 18 | 1 | 1 | No | No |
| 17959263 | SYSTEMS AND METHODS FOR CULTIVATING ALGAE | October 2022 | March 2024 | Allow | 17 | 2 | 1 | No | No |
| 17952813 | FORMULATIONS OF BIOLOGICS FOR INTRAVESICAL INSTILLATION | September 2022 | July 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17947798 | GALACTOOLIGOSACCHARIDES FOR PREVENTING INJURY AND/OR PROMOTING HEALING OF THE GASTROINTESTINAL TRACT | September 2022 | March 2024 | Abandon | 18 | 2 | 0 | No | No |
| 17900526 | MEANS AND METHODS FOR VISUALIZATION OF TISSUE STRUCTURES | August 2022 | May 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17881200 | HUMAN PLASMA-LIKE MEDIUM | August 2022 | September 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17876445 | REPAIR AND/OR RECONSTITUTION OF INVERTEBRAL DISCS | July 2022 | September 2023 | Abandon | 13 | 1 | 0 | No | No |
| 17814541 | METHOD OF OPERATION UTILIZING ELECTRIC FIELD FOR PROCESSING OF BLOOD TO NEUTRALIZE PATHOGEN CELLS THEREIN | July 2022 | December 2025 | Allow | 41 | 1 | 0 | No | No |
| 17858920 | METHODS FOR CULTURING ORGANOIDS | July 2022 | March 2025 | Allow | 33 | 4 | 1 | Yes | No |
| 17758405 | TECHNICAL METHOD FOR TREATING VITILIGO THROUGH HAIR FOLLICLE MELANOCYTE STEM CELL TRANSPLANTATION | July 2022 | October 2025 | Allow | 39 | 1 | 0 | No | No |
| 17849389 | EXOSOME AND PREPARATION PROCESS AND USE THEREOF | June 2022 | November 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17787909 | SUPERPARAMAGNETISM-MODIFIED AND NEUTROPHIL EXOSOME BIOMIMETIC VESICLE-BASED BIOLOGICAL PREPARATION FOR DRUG DELIVERY, AND PREPARATION METHOD THEREOF | June 2022 | December 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17778962 | METHODS AND SYSTEMS FOR PRODUCING SKIN GRAFTS | May 2022 | February 2026 | Allow | 44 | 2 | 1 | Yes | No |
| 17750874 | HUMAN MILK OLIGOSACCHARIDES TO PROMOTE GROWTH OF BENEFICIAL BACTERIA | May 2022 | April 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17746473 | CELL CULTURE MEDIA EXTENDING MATERIALS AND METHODS | May 2022 | November 2023 | Allow | 18 | 2 | 0 | No | No |
| 17768587 | USE OF ACELLULAR ADIPOSE TISSUE EXTRACT IN PROMOTING HAIR GROWTH AND RETENTION | April 2022 | September 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17715326 | ADVANCED FUNCTIONAL BIOCOMPATIBLE FOAM USED AS A HEMOSTATIC AGENT FOR ACUTE WOUNDS | April 2022 | July 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17696321 | BIOMATERIALS DERIVED FROM TISSUE EXTRACELLULAR MATRIX | March 2022 | April 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17761074 | ORGAN PERFUSION SYSTEM AND METHOD | March 2022 | October 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17641774 | KIT AND METHOD | March 2022 | December 2024 | Allow | 33 | 1 | 1 | No | No |
| 17579680 | FEED ADDITIVE FORMULATION AND METHODS OF MAKING AND USING THE SAME | January 2022 | March 2025 | Abandon | 38 | 4 | 1 | No | No |
| 17627353 | ORDERED PROCESSING OF BLOOD PRODUCTS TO PRODUCE THERAPEUTICALLY ACTIVE CELLS | January 2022 | July 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17576444 | ALGORIPHAGUS SP, BOSEA SP, BREVUNDIMONAS SP, DESULFOVIBRIO SP, MICROBACTERIUM SP, SPHINGOMONAS SP, AND VARIOVORAX SP FOR USE IN DISEASE PREVENTION AND TREATMENT | January 2022 | March 2025 | Abandon | 38 | 3 | 1 | No | No |
| 17597606 | IMPROVED BUFFER FOR THE CAPACITATION OF SPERMATOZOA | January 2022 | November 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17566234 | HUMAN SERUM ALBUMIN IN FORMULATIONS | December 2021 | March 2025 | Allow | 39 | 3 | 0 | Yes | No |
| 17622396 | CELL CULTURE METHODS AND COMPOSITIONS | December 2021 | October 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17559970 | TREATMENT OF HEART FAILURE AND/OR POST INFARCT PATHOLOGICAL REMODELING BY EX VIVO REPROGRAMMED IMMUNE CELLS | December 2021 | July 2025 | Allow | 42 | 2 | 0 | No | No |
| 17621403 | PANCREAS-ON-A-CHIP AND USES THEREOF | December 2021 | August 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17643464 | METHOD FOR PRODUCING CELL CLUSTER GROUP AND DEVICE FOR PRODUCING SAME | December 2021 | April 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17540450 | STABILIZED TWO-PART HEMATOXYLIN SOLUTION UTILIZING pH ADJUSTMENT | December 2021 | August 2025 | Allow | 44 | 4 | 1 | No | No |
| 17455466 | PROBIOTIC COMPOSITION INCLUDING LACTIC ACID BACTERIAL STRAINS AND USE THEREOF | November 2021 | December 2023 | Allow | 25 | 2 | 1 | Yes | No |
| 17609954 | GENERATING DORSAL FOREGUT, AND ANTERIOR DOMAIN, ENDODERM CELLS | November 2021 | June 2025 | Allow | 43 | 1 | 1 | No | No |
| 17607758 | COSMETIC COMPOSITION COMPRISING CULTURE SOLUTION OF MESENCHYMAL STEM CELLS CULTURED IN HPL-CONTAINING MEDIUM | October 2021 | May 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17606990 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DEGENERATION | October 2021 | June 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17505688 | CELLULAR CULTURE MEDIUM FREE FROM SERUM | October 2021 | May 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17604369 | USE OF A CYTOFLUOROMETRY METHOD FOR EVALUATING THE STABILITY AND VIABILITY OF A BIOMASS OF FREEZE-DRIED BACTERIAL CELLS | October 2021 | August 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17599895 | CAPSULE COMPRISING INSULIN-SECRETING CELLS FOR TREATING DIABETES | September 2021 | June 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17599458 | MATRIX COMPOSITION | September 2021 | June 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17442405 | CELL POPULATION INCLUDING PLURIPOTENT STEM CELLS AND PRODUCTION METHOD THEREOF | September 2021 | June 2025 | Abandon | 45 | 2 | 0 | Yes | No |
| 17477720 | LACTOBACILLUS PLANTARUM HG-23 AND APPLICATION THEREOF | September 2021 | January 2024 | Abandon | 28 | 2 | 1 | No | No |
| 17439277 | METHOD FOR MANUFACTURING LUMINAL STRUCTURE | September 2021 | July 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17472282 | METHODS OF TREATING DISEASES RELATED TO NET FORMATION WITH PARENTERAL ADMINISTRATION OF POLYSIALYLATED DNASE I | September 2021 | November 2023 | Abandon | 26 | 2 | 1 | No | No |
| 17467811 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CARTILAGE DISEASES | September 2021 | May 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17435478 | CULTURED TISSUE AND METHOD FOR PRODUCING SAME | September 2021 | January 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17394804 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | August 2021 | December 2023 | Allow | 28 | 3 | 0 | Yes | No |
| 17376226 | TISSUE HEALING AGENT | July 2021 | May 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17376084 | QUALITY OF A CELLULAR GRAFT | July 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17367231 | ANTIBIOTIC-FREE COMPOSITIONS FOR THE PREVENTION OR CONTROL OF COCCIDIOSIS | July 2021 | February 2023 | Allow | 20 | 1 | 0 | Yes | No |
| 17365207 | PHARMACEUTICAL COMPOSITION OR HEALTH FOOD FOR TREATING AND/OR ALLEVIATING NERVOUS DISEASES | July 2021 | August 2025 | Allow | 49 | 3 | 0 | No | No |
| 17339254 | DIAGNOSIS AND MONITORING OF LIVER DISEASE | June 2021 | May 2025 | Abandon | 47 | 2 | 1 | No | Yes |
| 17332461 | SYNTHETIC ATTACHMENT MEDIUM FOR CELL CULTURE | May 2021 | March 2023 | Allow | 22 | 1 | 0 | Yes | No |
| 17328517 | METHODS AND DEVICES FOR SIMULTANEOUS OPTICAL IRRADIATION AND OSCILLATING MAGNETIC FIELD RADIATION OF A TARGET | May 2021 | February 2023 | Allow | 21 | 1 | 0 | No | No |
| 17295849 | METHODS FOR EXPANSION OF NATURAL KILLER (NK) CELL SUBSET AND RELATED COMPOSITIONS AND METHODS | May 2021 | March 2025 | Allow | 46 | 1 | 1 | No | No |
| 17293413 | METHODS OF GENERATING MYCELIAL SCAFFOLDS AND APPLICATIONS THEREOF | May 2021 | January 2026 | Abandon | 56 | 2 | 1 | No | No |
| 17307234 | COMPOSITIONS AND METHODS FOR STABILIZING SUSCEPTIBLE COMPOUNDS | May 2021 | February 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17250968 | NOVEL GRAS PROBIOTIC BACTERIAL STRAIN TO INHIBIT ACIDOSIS AND LIVER ABSCESSES IN CATTLE | April 2021 | July 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17221750 | Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration | April 2021 | December 2023 | Allow | 32 | 2 | 0 | Yes | No |
| 17282065 | CELL CULTURE TOOL AND METHOD FOR PRODUCING CELL CULTURE TOOL | April 2021 | June 2025 | Allow | 51 | 2 | 1 | No | No |
| 17280702 | METHODS OF HUMAN RETINAL PROGENITOR CELL ISOLATION AND CULTURE | March 2021 | May 2025 | Allow | 49 | 2 | 0 | No | Yes |
| 17268854 | PROCESS FOR PURIFYING AN ANTIBODY FROM EGG YOLK, PRODUCTS AND USES THEREOF | February 2021 | April 2025 | Allow | 50 | 3 | 0 | No | No |
| 17165523 | HOST-GUEST METAL ORGANIC FRAMEWORK SYSTEMS | February 2021 | September 2023 | Allow | 32 | 2 | 0 | Yes | No |
| 17160090 | APPLICATION OF PHLEGMYHEATCLEAR IN PREPARATION OF DRUG FOR TREATMENT OF ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | January 2021 | January 2024 | Abandon | 36 | 4 | 0 | No | No |
| 17261533 | SOLUBILIZED APYRASES, METHODS AND USE | January 2021 | September 2024 | Allow | 43 | 1 | 1 | No | No |
| 17259644 | HALOPEROXIDASE COMPOSITIONS AND USES THEREOF | January 2021 | November 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17259161 | Method For Extracting And Isolating Lutein Crystal From Vegetable Oil Resin Containing Lutein Diester | January 2021 | November 2023 | Allow | 34 | 1 | 0 | No | No |
| 17137933 | NOVEL APPLICATION OF HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR FOR MEDICAL PURPOSES | December 2020 | July 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17256383 | IMMUNOMODULATORY COMPOSITIONS AND USES THEREOF | December 2020 | September 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17251155 | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | December 2020 | December 2024 | Abandon | 49 | 3 | 1 | No | No |
| 17058991 | METHOD FOR ENRICHING AND SEPARATING ANAEROBIC FIBER-DEGRADING BACTERIUM ON THE BASIS OF CELLULOSIC MAGNETIC NANOPARTICLES | November 2020 | April 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17057500 | METHODS OF SELECTING SUBJECTS FOR TREATMENT WITH METABOLOMIC MODULATORS | November 2020 | February 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17056724 | USE OF 3D-PRINTED FREESTANDING STRUCTURES FOR EX VIVO TISSUE | November 2020 | March 2026 | Allow | 60 | 3 | 1 | Yes | No |
| 17055678 | EXPANSION CULTURE METHOD FOR HUMAN-DERIVED NATURAL KILLER CELLS BY USING HDAC INHIBITOR | November 2020 | April 2025 | Allow | 53 | 3 | 0 | No | No |
| 17090401 | Multi-Dimensional Biomaterial and Method for Producing the Same | November 2020 | February 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17080018 | DICARBOXYLIC ACIDS AND CORRELATED COMPOUNDS AS A MEASURE OF RED BLOOD CELL QUALITY | October 2020 | February 2023 | Allow | 28 | 1 | 0 | No | No |
| 17074902 | SYSTEMS AND METHODS FOR CELL CULTURING | October 2020 | May 2024 | Allow | 43 | 8 | 1 | No | No |
| 17067560 | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | October 2020 | November 2023 | Abandon | 37 | 1 | 0 | No | No |
| 17066162 | HERPES SIMPLEX VIRUS (HSV) ANTICANCER THERAPIES | October 2020 | July 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17040881 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE AND FUSOBACTERIA-CAUSED OR RELATED DISEASES AND CONDITIONS | September 2020 | April 2025 | Abandon | 54 | 2 | 1 | No | Yes |
| 16981995 | METHODS AND COMPOSITIONS COMPRISING NEMATODE SIGNALLING COMPOUNDS | September 2020 | March 2024 | Allow | 42 | 2 | 1 | No | No |
| 16980889 | METHOD FOR ISOLATING AND CULTURING NEURAL STEM CELLS WITH HIGH EFFICIENCY | September 2020 | October 2024 | Allow | 49 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NGUYEN, NGHI V.
With a 46.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NGUYEN, NGHI V works in Art Unit 1653 and has examined 468 patent applications in our dataset. With an allowance rate of 52.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner NGUYEN, NGHI V's allowance rate of 52.1% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by NGUYEN, NGHI V receive 2.97 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by NGUYEN, NGHI V is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +53.3% benefit to allowance rate for applications examined by NGUYEN, NGHI V. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.0% of applications are subsequently allowed. This success rate is in the 12% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 16.0% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 26.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 30% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 58.3% of appeals filed. This is in the 32% percentile among all examiners. Of these withdrawals, 47.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 78.0% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 63% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.8% of allowed cases (in the 59% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.